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Most of the studies present in the literature show a high prevalence, and incidence, of 
new cases of hypothyroidism and autoimmune thyroiditis (AT) in systemic lupus erythe-
matosus (SLE) patients, overall in female gender. A limited number of cases of Graves’ 
disease have been also reported in SLE patients, in agreement with the higher preva-
lence of thyroid autoimmunity. It has been also demonstrated that a Th1 predominance 
is associated with AT in SLE patients. Furthermore, a higher prevalence of papillary 
thyroid cancer has been recently reported in SLE, in particular in the presence of thyroid 
autoimmunity. However, studies in larger number of SLE patients are needed to confirm 
findings about thyroid cancer. On the whole, data from literature strongly suggest that 
female SLE patients, with a high risk (a normal but at the higher limit thyroid-stimulating 
hormone value, positive antithyroid peroxidase antibodies, a hypoechoic pattern, and 
small thyroid), should undergo periodic thyroid function follow-up, and appropriate 
treatments when needed. A careful thyroid monitoring would be opportune during the 
follow-up of these patients.
Keywords: systemic lupus erythematosus, autoimmune thyroiditis, hypothyroidism, Graves’ disease, thyroid 
cancer, AbTPO, AbTg, CXCL10
inTRODUCTiOn
Systemic lupus erythematosus (SLE) is an autoimmune disease affecting mostly joints, skin, blood 
vessels, heart, lungs, kidneys, liver, and nervous system, in which the immune system attacks tissues 
and cells leading to inflammation and damage (1). The course of SLE is variable, with periods of exac-
erbation (called flares) alternating with periods of remission. SLE occurs nine times more often in the 
female gender than in male, and it is more frequent in people of non-European descent (1). Different 
types of autoantibodies are present in SLE patients (2). The difference of clinical features of SLE in 
different patients is due to the complexity of the risk factors (genetic, hormonal, and environmental), 
and the variety of circulating autoantibodies present (2, 3). Because of the presence of many different 
autoantibodies, SLE is classified as a “B-cell disease.” Circulating blood lymphocytes in SLE patients 
show a Th2-like profile (4); however, Th1 lymphocytes and interferon (IFN)-γ have been demon-
strated to be important for the immune pathogenesis of SLE (5). In fact, it has been shown that the 
Abbreviations: AbM, antimicrosomal antibodies; AbTg, anti-thyroglobulin antibodies; AbTPO, antithyroid peroxidase 
antibodies; AH, autoimmune hypothyroidism; AITD, autoimmune thyroid disorders; AOR, adjusted odds ratio; APS, 
antiphospholipid syndrome; AT, autoimmune thyroiditis; ESS, euthyroid sick syndrome; GD, Graves’ disease; IFN, interferon; 
IL, interleukin; OR, odds ratio; PTC, papillary thyroid cancer; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; 
SLEDAI, SLE disease activity; SS, Sjögren’s syndrome; T4, thyroxine; T3, triiodothyronine; TBII, TSH-binding inhibitor 
immunoglobulin; ThyAb, thyroid autoantibodies; TNF, tumor necrosis factor; TSH, thyroid-stimulating hormone; TSI, 
thyroid-stimulating immunoglobulins.
TAbLe 1 | Prevalence of thyroid autoimmunity in SLE patients versus controls, in the studies that have an internal control matched by gender and age.
Reference SLe patients 
(n)
AiTD% in SLe patients Controls  
(n)
AiTD% in controls P
Antonelli et al. (7) 213 Thyroid autoimmunity 
34.7%
426 Thyroid autoimmunity 15.1% <0.001
Antonelli et al. (8) 153 AbTg or AbTPO positivity 
33%; AbTg and AbTPO 
positivity 12%
459 iodine-deficient 
controls and 459 
iodine-sufficient 
controls
AbTg or AbTPO positivity 11% in iodine-
deficient controls; AbTg or AbTPO positivity 
13% in iodine-sufficient controls; AbTg and 
AbTPO positivity 2% in iodine-deficient 
controls; AbTg and AbTPO positivity 3% in 
iodine-sufficient controls
<0.0001 for AbTg 
or AbTPO positivity; 
0.001 for AbTg and 
AbTPO positivity
Weetman and Walport (14) 41 ThyAb 51% 41 ThyAb 27% <0.05
Vianna et al. (17) 100 ThyAb 21%; AbTg 11% 100 ThyAb 16%; AbTg 2% 0.009 for AbTg
Mihailova et al. (23) 12 children with 
SLE
AbTg 58% 27 children having 
juvenile chronic 
arthritis
AbTg 63% autoimmune thyroiditis 44.4% Not reported
Shahin et al. (24) 45; AbTg and 
AbM were 
assessed in 27 
patients
AbTg 18.5% 20 0 ns
Mader et al. (27) 77 AbTg 7.8%; AbTPO 5.2% 52 AbTg 7.7%; AbTPO 7.7% ns
Appenzeller et al. (28) 524 Symptomatic AITD was 
observed in 6.1%
50 Symptomatic AITD was observed in 2% >0.05
Lazúrová et al. (29) 80 patients with 
SLE or RA (12 
SLE and 68 RA)
Prevalence of AITD 24% 34 Prevalence of AITD 8% <0.05
Kumar et al. (30) 100 Prevalence of ThyAb 30% 100 Prevalence of ThyAb 10% <0.05
Lin et al. (33) 1,633 Cumulative incidence of 
thyroid disease 8.1%
6,532 Cumulative incidence of thyroid disease 
16.9%
<0.001
AbM, antimicrosomal antibodies; AITD, autoimmune thyroid disorders; AbTg, anti-thyroglobulin antibodies; AbTPO, anti-thyroperoxidase antibodies; RA, rheumatoid arthritis; SLE, 
systemic lupus erythematosus; ThyAb, thyroid autoantibodies.
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assistance of the Th1 lymphocytes is necessary for the development 
of the disease, and in the absence of a functioning Th1 immune 
response “helpless” B cells are not functional enough to trigger 
SLE inflammation (6). Circulating autoantibodies, immune com-
plex deposition, and complement activation are SLE hallmarks; 
however, a growing body of evidence has shown the importance of 
cytokines/chemokines in this disease, such as interleukin (IL)-6, B 
lymphocyte stimulator, IL-17, type I IFNs, tumor necrosis factor 
(TNF)-α, and Th1 chemokines. These cytokines/chemokines are 
important in the orchestration, maturation, differentiation, and 
activation of various immune competent cells, which mediate the 
local inflammation and produce the tissue injury.
Systemic lupus erythematosus is associated with many other 
autoimmune diseases, and autoimmune thyroid disorders 
(AITD) too (7, 8).
Here, we review the scientific literature about the association 
of SLE and AITD.
THe ASSOCiATiOn OF SLe AnD AiTD
After the initial case reports describing a coexistence of SLE 
and AITD, many systematic studies have evaluated the possible 
association of SLE and AITD (Table 1).
Prevalence of Thyroid Autoantibodies 
(ThyAb) in SLe Patients
Serological overlap among SLE, rheumatoid arthritis (RA), and 
AITD exists (9–12).
A first study evaluated thyroid disorders in 319 SLE patients 
showing 9 with thyrotoxicosis, 3 with hypothyroidism, and 2 with 
thyroiditis, suggesting a higher prevalence of thyroid disorders in 
SLE patients (13). Weetman and Walport compared the prevalence 
of ThyAb and abnormal thyroid-stimulating hormone (TSH) 
levels in 41 SLE patients, versus age- and sex-matched controls. 
A significant higher prevalence of ThyAb (51%) was observed 
in SLE compared to (27%) controls. Furthermore, hypothyroid-
ism was observed in 10 SLE patients and 5 controls, usually in 
association with circulating ThyAb (14). In another study, 18% 
of SLE patients had positive antimicrosomal antibodies (AbM). 
Euthyroid sick syndrome (ESS) was diagnosed in 15% of SLE 
patients, and true or initial primary hypothyroidism in 5, and 39%, 
respectively. ThyAb were present in 45% of SLE patients with high 
TSH (15). Anti-TSH receptor antibodies were also evaluated in 28 
SLE patients with thyroid disorders. 10/28 patients demonstrated 
thyroid-stimulating immunoglobulins (TSI) activity, while 5 
patients had evidence of TSH-binding inhibitor immunoglobulin 
(TBII) activity. The TSI, or TBII activity, was not associated with 
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the abnormal thyroid function tests (16). Vianna et  al. studied 
100 SLE patients for the presence of ThyAb and thyroid disease. 
The ThyAb were similar in SLE (21%) and controls (16%); AbTg 
were present in 11% SLE and only 2% controls; AbM levels were 
also different (median levels: SLE = 400; controls = 100). A higher 
frequency of clinical thyroid disease was observed in SLE patients 
with ThyAb (5/21; 3 hypothyroid, 2 hyperthyroid) than in those 
without (1/79). SLE patients with ThyAb were significantly older 
(mean age 47.5 years) than those without (mean age 37.5 years) 
(17). In a group of SLE female patients, thyroxine (T4) was sig-
nificantly lower than in controls and 45.5% of patients with active 
SLE presented ThyAb. TSH basal, and after TRH stimulation, 
were significantly higher in patients with active SLE. ThyAb were 
not found in patients with inactive SLE (18). In 45 Chinese SLE 
patients, 24 (53.3%) had altered echographic findings. AbM and/
or AbTg were reported in 21 patients (46.7%), and TBII in only 
one. Ten patients (22.2%) showed an altered thyroid function. 
Hashimoto’s thyroiditis was reported in four patients (8.8%), two 
of whom had hypothyroidism. The mean disease duration was 
longer in patients with thyroid anomalies (P < 0.05) (19). Among 
129 SLE patients from Singapore, 8.9% had hyperthyroidism, 
3.9% Hashimoto’s thyroiditis, and 47.8% ESS. AbM or AbTg were 
present in 32.2% (20). Kausman and Isenberg evaluated 150 SLE 
patients, showing that 31 (21%) were ThyAb positive. Follow-up 
data were available on 20 ThyAb positive patients (average of 
7.9 years), of whom 12 (60%) were persistently ThyAb positive, 
while 8 (40%) were negative on at least one occasion during the 
follow-up. Five cases of clinical thyroid disease that were diag-
nosed, and 2/3 cases of subclinical elevation of TSH, occurred in 
the group with persistently positive ThyAb. Four (9%)/46 (among 
the 119) patients who initially were ThyAb negative, became 
ThyAb positive after a mean of 6.2  years; one had an elevated 
TSH (21). Among 37 SLE patients, positive anti-thyroperoxidase 
antibodies (AbTPO) were found in 11 (61%) of 18 patients with 
AbM, and in 3 (16%)/19 without (22). In 12 children with active 
SLE, aged 5–18  years, AbTg were positive in 7/12. The serum 
levels of triiodothyronine (T3), T4, and TSH were in the reference 
limits in all SLE children (23). Forty-five Egyptian SLE patients 
(43 women and 2 men) were evaluated for thyroid disorders, versus 
a group of 20 normal females. The mean serum free T3 levels in 
all patients were significantly lower than in controls (1.89 ± 1.14 
versus 3.15 ± 0.93 pg/ml; P < 0.05), overall in patients treated with 
cyclophosphamide. Also serum free T4 levels in SLE patients were 
significantly lower than in controls. Two of 45 patients (4.4%) had 
primary hypothyroidism. The mean serum TSH levels in SLE 
patients were significantly higher than in controls (4.82 ±  22.2 
versus 2.65 ± 1.18 μIU/ml; P < 0.001). Among six patients with 
decreased TSH levels, one showed decreased T3 and T4, two had 
decreased T4 only (24). In another study, the prevalences of HT, 
or Graves’ disease (GD) in SLE patients, were 90-fold, and 68-fold, 
higher than in the general population (25).
Autoimmune thyroid disorders were evaluated in families 
with more than one SLE patient. Among 1,138 SLE patients, 169 
had a diagnosis of Sjögren’s syndrome (SS), of whom 50 (29.6%) 
also had AITD. Among the 939 patients with SLE without SS, 
119 (12.7%) had AITD. Among 2,291 SLE-unaffected relatives, 
44 had diagnosed primary SS and 16 (36.3%) of these also had 
autoimmune thyroid disease. 265/2,247 (11.8%) subjects had 
autoimmune thyroid disease. These findings suggested that auto-
immune thyroid disease is observed in excess among SLE patients 
with a diagnosis of secondary SS, as among their SLE-unaffected 
relatives with a diagnosis of primary SS (26). Seventy-seven SLE 
patients were studied for thyroid disorders, against 52 controls. 
Hypothyroidism was reported in 11.6% of SLE patients compared 
to 1.9% of controls. None of the patients or controls had hyper-
thyroidism. No statistically significant difference was observed 
in the levels of anti-thyroglobulin antibodies (AbTg) or AbTPO 
between the study group and the control group. No association 
was found between the SLE disease activity (SLEDAI) score and 
the prevalence of ThyAb (27). In 524 patients with SLE, AITD were 
evaluated, versus 50 female adults. 32/524 (6.1%) SLE patients and 
1/50 controls had symptomatic autoimmune thyroid dyfunctions, 
in particular hypothyroidism (28 SLE patients versus 1 control). 
Sixty (11.5%) SLE patients had subclinical thyroid diseases and 
89/524 (17%) had positive ThyAb in absence of thyroid dysfunc-
tions. ThyAb forerun the appearance of clinical autoimmune 
thyroid disease in 70% of SLE patients. SS and positive rheumatoid 
factor were more frequent in SLE patients with AITD than in those 
without. SLEDAI was correlated with the presence of hyperthy-
roidism (28). The prevalence of AITD in 80 patients with SLE or 
RA was significantly higher than in the 34 controls (24 versus 8%, 
P < 0.05) (29). Two hundred thirteen SLE patients were evaluated 
by assessing thyroid hormones, the presence of ThyAb, and thy-
roid ultrasonography with respect to 426 controls (matched by age 
and gender), from the same geographic area, with a well-defined 
status of iodine intake. In female SLE patients versus controls, the 
odds ratio (OR) was 4.5 [95% confidence interval (CI), 2.5–8.4] for 
subclinical hypothyroidism; 2.9 (95% CI, 2.0–4.4) for thyroid auto-
immunity; and 2.6 (95% CI, 1.7–4.1) for AbTPO positivity. Female 
SLE patients had significantly (P < 0.01) higher mean values of 
TSH and AbTPO than controls, as a significantly (P < 0.01) higher 
prevalence of clinical hypothyroidism and GD. In this study, 3% of 
SLE patients had “non-thyroidal illness syndrome” versus 0 con-
trols (7). Hundred SLE patients were also evaluated for AITD, in 
comparison with 100 controls (matched by sex and age). Thyroid 
dysfunction was reported in 36 (36%) (all women) SLE patients 
[14 (14%) with clinical hypothyroidism, 2 (2%) with subclinical 
hyperthyroidism, and 12 (12%) with subclinical hypothyroidism], 
versus 8 (8%) of controls. Eight patients (8%) had isolated low T3 
in agreement with ESS. Eighteen (50%) of thyroid dysfunctions 
were of autoimmune origin with positive autoantibodies, but not 
the other 18 (50%). Twelve (12%) of SLE patients had elevated 
ThyAb alone, while only five (5%) of controls had primary hypo-
thyroidism and three (3%) had subclinical hypothyroidism, and 
no cases of hyperthyroidism were reported. SLEDAI and thyroid 
dysfunction of sick euthyroid type were significantly associated. 
Prevalence of ThyAb in SLE patients was 30% with respect to 10% 
of controls. There were no other autoimmune endocrine diseases 
such as diabetes or Addison’s disease in SLE patients (30). Among 
a total of 63 pregnant SLE women, 13% were on thyroid hormone 
prior to becoming pregnant, 11% were diagnosed with hypo-
thyroidism during pregnancy, and 14% developed postpartum 
thyroiditis. The prevalence of preterm delivery was 67% in women 
with thyroid disease and 18% in women who were thyroid disease 
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free. The presence of ThyAb was not correlated with preterm 
delivery. This study suggests that pregnant women with SLE have 
an increased prevalence of thyroid disease. Women with SLE and 
thyroid disease have an increased prevalence of preterm delivery 
(31). The prevalence of thyroid diseases was retrospectively 
analyzed in 1,006 Chinese SLE patients. The prevalence of AITD 
was 2.78%, central hypothyroidism 1.29%, clinical hypothyroid-
ism 1.69%, subclinical hypothyroidism 10.04%, hyperthyroidism 
1.19%, ESS 9.54%, and nodules 1.09%, respectively. Subclinical 
hypothyroidism was more prevalent (10.04%) in this study, than 
the prevalence of thyroid abnormalities in the general Chinese 
population (0.91–6.05%). Moreover, patients with lupus nephritis 
had subclinical hypothyroidism more frequently (13.4%) than 
those without (7.3%, P = 0.001) (32).
However, discordant results have been recently reported (33). 
In 1,633 SLE patients of new diagnosis, the prevalence of hyper-
thyroidism, hypothyroidism, and autoimmune thyroiditis (AT) 
was compared with 6,532 controls (matched by sex and age). 
The cumulative incidence of thyroid disease in SLE patients was 
lower than in control subjects (8.1 versus 16.9%, P < 0.001). The 
authors suggested that SLE patients had a significantly lower rate 
of thyroid diseases and hyperthyroidism than matched controls 
(33). The reported study could have some limitations, able to affect 
the results, to be considered: (1) it was based on diagnostic codes 
released from The National Health Insurance Research Database, 
and for this reason details on thyroid serological assessments, 
presence of ThyAb, or SLE autoantibodies were not available; 
(2) data obtained in a retrospective cohort study are usually infe-
rior in statistical quality to those derived from randomized trials 
because of the potential biases related to adjustments for confound-
ing variables (33). A total of 376 Colombian SLE patients were 
evaluated for the presence of (1) confirmed autoimmune hypothy-
roidism (AH), (2) positive AbTPO/AbTg without hypothyroidism, 
(3) non-AH, and (4) SLE patients with neither. Confirmed AH 
prevalence was 12%. AbTg and AbTPO were reported in 10% and 
21% euthyroid SLE patients, respectively. Patients with confirmed 
AH were significantly older and had later age at the onset of 
the disease. SS [adjusted OR (AOR) 23.2, 95% CI, 1.89–359.53, 
P = 0.015], smoking (AOR 6.93, 95% CI, 1.98–28.54, P = 0.004), 
and positive anticyclic citrullinated peptide (AOR 10.35, 95% CI, 
1.04–121.26, P = 0.047) were associated with AH in SLE patients. 
Female gender, smoking, older age, SS, certain autoantibodies, 
and articular and cutaneous involvement were associated with 
this polyautoimmunity (34). Another meta-analysis evaluated the 
association of SLE and thyroid autoimmunity; a total of 1,076 SLE 
cases and 1,661 healthy controls were included. The meta-analysis 
results showed that the prevalence of ThyAb positivity in SLE 
patients was higher than in healthy controls (AbTg: OR = 2.99, 95% 
CI, 1.83–4.89; AbTPO: OR = 2.20, 95% CI, 1.27–3.82, respectively) 
(35). The frequency of AITD among 189 SLE patients was 6.3%, 
with 2.6% in the hyperthyroid group and 3.7% in the hypothyroid 
group. A new association between AITD and antiphospholipid 
syndrome was shown (36). Five thousand and eighteen patients 
with SLE and 25,090 age- and sex-matched controls were evaluated 
for thyroid dyfunctions. The proportion of hypothyroidism in SLE 
patients was increased with respect to the prevalence in controls 
(15.58 and 5.75%, respectively, P  <  0.001). In a multivariate 
analysis, SLE was associated with hypothyroidism (OR =  2.644, 
95% CI, 2.405–2.908) (37). Conversely, a recent study evaluated 
prospectively the prevalence of other autoimmune disorders in 
outpatient clinic in 3,069 consecutive patients with diagnosed 
chronic AT, versus two age- and sex-matched control groups: 
(a) a control group of 1,023 subjects, drawn from a random sample 
of the general population without thyroid disorders and (b) 1,023 
patients with non-toxic multinodular goiter from the same ran-
dom sample of the general population, with similar iodine intake. 
The results of the study demonstrated a significant increase of SLE 
prevalence in AT patients (versus both controls) (38).
Th1 and Th2 Cytokines in SLe
The ratios of Th1 and Th2 cytokines have been investigated to 
determine the cytokine homeostasis in SLE. Even if SLE was 
thought to be a Th2-polarized disease (39), more recently signifi-
cantly elevated circulating cytokines of Th1 response, including 
TNF-α, and IFN-γ were also shown in SLE patients (40–42). 
Chemokine IFN-γ-inducible protein 10, the prototype of the 
chemokine (C-X-C motif) family, has chemotactic activity espe-
cially for activated Th1 cells and is involved in the pathogenesis 
of various Th1-dominant autoimmune diseases (43), and in SLE. 
Also AITD are Th1 immune-mediated autoimmune disorders in 
which Th1 lymphocytes, IFN-γ, and IFN-γ-dependent chemokines 
(CXCL9, CXCL10, CXCL11) play an important role (44–46). The 
common Th1 immune predominance in AITD and SLE should 
be the immunopathogenetic base of the association of these two 
diseases. On the whole, the abovementioned results show a high 
prevalence, and incidence, of new cases of hypothyroidism and 
AT in SLE patients, and suggest that female patients with systemic 
sclerosis, who are at high risk [a borderline high (even if in the 
normal range) TSH value, positive AbTPO, and a hypoechoic and 
small thyroid] should have periodic thyroid function follow-up.
THYROiD AbnORMALiTieS AnD 
CLiniCAL ASPeCTS OF SLe
Many studies have tried to associate thyroid abnormalities with 
clinical findings of SLE, with different results.
An association between hypothyroidism, or AITD, and SLE 
clinical activity has been described in few studies (18, 28).
While another study found an association between SLEDAI 
score and ESS (30).
The reported data suggested that AITD is found more fre-
quently among patients with SLE with a diagnosis of secondary 
SS, but not in SLE patients without SS (26, 28).
However most of the studies were not able to find any associa-
tion among thyroid autoimmunity or thyroid dysfuntions, and 
clinical or serological features of SLE.
SLe AnD PAPiLLARY THYROiD  
CAnCeR (PTC)
A first prospective study investigated the prevalence and features 
of thyroid cancer in 153 unselected SLE patients in comparison 
with two population-based, control groups (matched by sex and 
age): (1) 459 iodine-deficient controls and (2) 459 iodine-sufficient 
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controls. SLE patients had circulating TSH, AbTg and AbTPO 
levels significantly higher (P < 0.001 for all), and a higher preva-
lence of hypothyroidism (P < 0.001), than controls. Five PTC cases 
were reported in SLE patients, none in iodine-deficient controls 
(P = 0.001), and only one was shown in iodine-sufficient controls 
(P =  0.001). Thyroid autoimmunity was shown in 80% of SLE 
patients with confirmed thyroid cancer, and only in 31% of SLE 
patients without thyroid cancer (P = 0.02). These findings sug-
gested that PTC prevalence in SLE patients is more elevated than 
in controls, especially in the presence of thyroid autoimmunity 
(8). Another study showed that among 16,409 patients [121,283 
(average 7.4) person-years], 644 cases of cancer occurred, in 
particular hematologic ones, and a raised risk of thyroid cancer 
(SIR 1.76, 95% CI, 1.13–2.61) was observed too (47). A systematic 
review with meta-analysis investigated the risk of thyroid cancer 
in SLE revealing the positive association between thyroid cancer 
and SLE risk (48). A further meta-analysis assessed the asso-
ciation of SLE and malignancy evaluating 16 papers, including 
59,662 SLE patients. The pooled relative risks were 1.28 (95% CI, 
1.17–1.41) for overall cancer, 1.78 (95% CI, 1.35–2.33) for thyroid 
cancer (49). Also other studies confirmed the association between 
SLE and thyroid cancer (50).
COnCLUSiOn
Most of the studies show high prevalence, and incidence, of new 
cases of hypothyroidism and AT in SLE patients, overall in female 
gender. A limited number of GD cases have been also reported in 
SLE, in agreement with the higher prevalence of thyroid autoim-
munity. It has been also demonstrated that Th1 predominance is 
associated with AT in SLE patients.
Furthermore, a higher prevalence of PTC has been recently 
reported in SLE patients, overall in the presence of thyroid auto-
immunity. However, studies in larger number of SLE patients are 
needed to confirm data about thyroid cancer.
On the whole, data from literature strongly suggest that female 
SLE patients, with a high risk (a normal but at the higher limit 
TSH value, positive AbTPO, a hypoechoic pattern, and small thy-
roid) should undergo periodic thyroid function follow-up, and 
appropriate treatments when needed. However, studies in larger 
number of patients are required to evaluate if routine thyroid 
screening could be beneficial for SLE patients.
A careful thyroid monitoring would be opportune during the 
follow-up of these patients.
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